



(11) **EP 1 609 804 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
13.06.2012 Bulletin 2012/24

(51) Int Cl.:
C07K 16/40 (2006.01) **A61K 39/00** (2006.01)
A61P 7/04 (2006.01) **C12N 9/64** (2006.01)
G01N 33/53 (2006.01) **G01N 33/564** (2006.01)

(21) Application number: **04721377.2**

(86) International application number:
PCT/JP2004/003602

(22) Date of filing: **17.03.2004**

(87) International publication number:
WO 2004/083250 (30.09.2004 Gazette 2004/40)

(54) **CONSTRUCT COMPRISING RECOGNITION DOMAIN OF ANTIBODY AGAINST VON WILLEBRAND FACTOR-SPECIFIC CLEAVING ENZYME**

KONSTRUKT ENTHALTEND DIE ERKENNUNGSDOMÄNE VON ANTIKÖRPERN GEGEN DAS VON WILLEBRAND FACTOR-SPECIFIC CLEAVING ENZYME

CONSTRUCTION CONTENANT UN DOMAINE DE RECONNAISSANCE D'ANTICORPS CONTRE UNE ENZYME DE CLIVAGE SPECIFIQUE DU FACTEUR DE VON WILLEBRAND

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

(74) Representative: **HOFFMANN EITLE**
Patent- und Rechtsanwälte
Arabellastraße 4
81925 München (DE)

(30) Priority: **17.03.2003 JP 2003071979**

(43) Date of publication of application:
28.12.2005 Bulletin 2005/52

(56) References cited:
EP-A- 1 391 516 EP-A- 1 544 293
JP-A- 10 500 705

(73) Proprietor: **Juridical Foundation**
The Chemo-Sero-Therapeutic Research Institute
Kumamoto-shi,
Kumamoto 860-8568 (JP)

- **SOEJIMA K ET AL: "A NOVEL HUMAN METALLOPROTEASE SYNTHESIZED IN THE LIVER AND SECRETED INTO THE BLOOD: POSSIBLY, THE VON WILLEBRAND FACTOR-CLEAVING PROTEASE?" JOURNAL OF BIOCHEMISTRY, JAPANESE BIOCHEMICAL SOCIETY / OUP, TOKYO, JP, vol. 4, no. 130, October 2001 (2001-10), pages 475-480, XP001079224 ISSN: 0021-924X**
- **SOEJIMA KENJI ET AL: "Analysis on the molecular species and concentration of circulating ADAMTS13 in blood" JOURNAL OF BIOCHEMISTRY (TOKYO), vol. 139, no. 1, January 2006 (2006-01), pages 147-154, XP002380916 ISSN: 0021-924X**
- **PLAIMAUER B. ET AL: 'Epitope Mapping of Anti-ADAMTS-13 Antibodies in Patients with Acquired TTP' BLOOD vol. 102, no. 11, 16 November 2003, page 540A, XP002979371**

(72) Inventors:

- **SOEJIMA, Kenji,**
c/o Kikuchi Research Center
Kikuchi-shi,
Kumamoto 869-1298 (JP)
- **NAKAGAKI, Tomohiro,**
c/o Kikuchi Research Center
Kikuchi-shi,
Kumamoto 869-1298 (JP)
- **MATSUMOTO, Masanori**
Kashihara-shi,
Nara 6348521 (JP)
- **FUJIMURA, Yoshihiro**
Kashihara-shi,
Nara 6348521 (JP)

EP 1 609 804 B1

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- PLAIMAUER B. ET AL: 'Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13)' BLOOD vol. 100, no. 10, 15 November 2002, pages 3626 - 3632, XP002979372
- GERRITSEN H.E. ET AL: 'Partial amino acid sequence of purified von Willebrand Factor-cleaving protease' BLOOD vol. 98, no. 6, 15 September 2001, pages 1654 - 1661, XP002201351
- HUANG C.-C. ET AL: 'Epitope mapping of factor VIII inhibitor antibodies of Chinese origin' BRITISH JOURNAL OF HAEMATOLOGY vol. 113, no. 4, June 2001, pages 915 - 924, XP002979373
- NARDI M.A. ET AL: 'GPIIIa-(49-66) is a major pathophysiologically relevant antigenic determinant for anti-platelet GPIIIa of HIV-1-related immunologic thrombocytopenia' PNAS USA vol. 94, no. 14, 08 July 1997, pages 7589 - 7594, XP002952277
- KOKAME K. ET AL: 'Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity' PNAS USA vol. 99, no. 18, 03 September 2002, pages 11902 - 11907, XP002979374
- CAL S. ET AL: 'Cloning, expression analysis, and structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains' GENE vol. 283, no. 1-2, 23 January 2002, pages 49 - 62, XP004339892

Description

Technical Field

5 **[0001]** The present invention relates to the field of ethical drugs. Specifically, the present invention relates to an epitope recognized by an antibody (hereinafter, also referred to as an anti-ADAMTS-13 antibody) against cleaving protease (hereinafter, also referred to as ADAMTS-13) specific to von Willebrand factor (hereinafter, also referred to as vWF) involved in blood coagulation, and to a polypeptide comprising the epitope region.

10 **[0002]** The polypeptide or a peptide fragment thereof provided by the present invention, which comprises an epitope region recognized by an antibody against ADAMTS-13 opens up the possibility of diagnosis given on the presence or absence of an autoantibody against ADAMTS-13 or an absorbing agent for the autoantibody or ADAMTS-13 replacement therapy for a patient with diseases associated with positivity for the autoantibody.

Background Art

15 **[0003]** vWF is a blood coagulation factor that is produced in a vascular endothelial cell and a megakaryocyte and is present as a multimer structure (with a molecular weight of 500 to 20,000 kDa) where single subunits each composed of 2050 amino acid residues (approximately 250-kDa monomers) are bound through a S-S bond. The concentration of vWF in blood is approximately 10 μ g/ml, and in general, vWF with a higher molecular weight has higher specific activity.

20 **[0004]** The vWF has two major functions as a blood coagulation factor, one of which is a function as a carrier protein that binds to and thereby stabilizes blood coagulation factor VIII and another of which is a function of helping platelets adhere and aggregate to the tissue beneath vascular endothelial cells of injured vascular walls to form platelet thrombi.

25 **[0005]** Thrombotic thrombocytopenic purpura (hereinafter, also referred to as TTP) is a disease that causes platelet thrombi in body tissue arterioles and capillary vessels in the whole body. In spite of the current progression of medical technology, the mortality associated with the disease has increased approximately threefold from 1971 to 1991. Pathologically, the TTP is considered to be caused by vascular endothelia cell injury and platelet aggregation in blood vessels. Immunohistologically, the presence of vWF in large amounts is observed in generated platelet thrombi, and the vWF is considered to play a crucial role in the pathogenesis of the disease. TTP is broadly divided into familial (congenital) TTP likely to have an inheritance factor and acquired (idiopathic) TTP developed especially in adults. Normal or high-molecular-weight vWF multimer structures are dominant in TTP patients. Especially, unusually large vWF multimer (ULvWFM) and large vWF multimer (LvWFM) are presumed to play a crucial role in the promotion of platelet aggregation and microthrombus formation under high shearing stress. On the other hand, vWF has been known to undergo digestion at the location between 842Tyr and 843Met by the action of vWF-cleaving protease under high shearing stress in circulating blood of healthy individuals. Thus, a probable scenario of how TTP is caused is as follows: the activity of the protease in plasma is reduced for some reason and ULvWFM or LvWFM is increased to accelerate platelet aggregation, followed by platelet thrombus formation in the blood vessel.

35 **[0006]** In 2001, a gene encoding vWF-cleaving protease also known as ADAMTS-13 that is an active body having the activity of the protease described above was cloned by the present inventors (JP Patent Publication (Kokai) No. 2003-284570). The findings about the molecular structure of ADAMTS-13 are summarized below. The location of a residue number that is numbered from methionine encoded by an initiation codon (ATG) is shown as a rough guide within parentheses (see SEQ ID No. 1).

40 **[0007]** The domain structure of ADAMTS-13 has a signal peptide preceding a propeptide that ends in a RQRR sequence as a furin cleavage motif, followed by a metalloprotease domain containing a reprotolysin-type zinc-chelating region consisting of HEXXHXXGXXHD as a consensus sequence (to amino acid residue No. 284 (p285X)); via a disintegrin-like domain as found in snake venom metalloprotease (to amino acid residue No. 386 (W387X)), there exists a first Tspl motif (Tspl-1) consisting of approximately 50 to 60 residues generally considered to be important for molecular recognition (to amino acid residue No. 448 (Q449X)), which continues to a Cys-rich region containing a RGDS sequence as one of cell adhesion motifs (to amino acid residue No. 580 (T581X)); and, through a spacer domain consisting of approximately 130 amino acid residues with no cysteine residue (to amino acid residue No. 687 (W688X)), additional Tspl motif repeats (Tspl-2 to Tspl-8) follow, which is followed by a CUB domain-1, and -2 that are said to be first found in a complement component C1r or C1s.

45 **[0008]** By the way, no finding about a major neutralizing epitope region in ADAMTS-13 has been obtained so far. In addition, a convenient diagnostic method for a patient positive for an autoantibody against the protease has not been established.

50 **[0009]** In light of such circumstances, a first object of the present invention is directed to an invention relating to the identification of a neutralizing epitope present on ADAMTS-13 and a neutralizing/absorbing agent for an antibody thereby proposed, which is mainly intended for an autoantibody.

[0010] A second object of the present invention is to provide a neutralizing/absorbing agent as defined in claim 2.

[0011] A third object of the present invention is to provide the neutralizing/absorbing agent for antibody measurement, wherein an autoantibody in a TTP patient is an object to be detected.

[0012] Disclosed is a method of producing a full-length or partially modified molecule of vWF-specific cleaving protease, which is obtained by modifying the epitope.

5 **[0013]** Also disclosed is fifth object of the present invention is to provide an application of the full-length or partially modified molecule of vWF-specific cleaving protease, which is obtained by modifying the epitope.

[0014] Up to now, plasmapheresis has been provided as treatment to a patient congenitally deficient in vWF-specific cleaving protease and a patient with acquired production of an antibody against the protease. Therefore, there is a demand for the establishment of replacement therapy with pure vWF-specific cleaving protease such as the protease purified or genetically altered. It has been reported that a familial TTP patient is congenitally deficient in vWF-specific cleaving protease and non-familial TTP is caused by the acquired production of an autoantibody against the protease. Thus, replacement therapy with the protease is preferred for a familial TTP patient (in reality, plasma administration is given to the patient), while a non-familial TTP patient requires the removal of an autoantibody by plasma exchange as well as the supplementation of the protease.

10 **[0015]** However, in the administration of ADAMTS-13 for supplementation to a patient positive for an autoantibody, an antibody against the protease, that is, an autoantibody, present in blood of the patient neutralizes the administered protease. As a result, the protease loses enzyme activity and has substantial reduction in concentration. However, the use of a neutralizing region identified by a method of determining an epitope for an antibody against ADAMTS-13 disclosed in a previous application (JP Patent Application No. 2002-279924) or identified by the present invention as well as the preparation of a partially modified molecule of a neutralizing epitope region that can be newly identified by Western blotting of competitive inhibition assay used in the present invention allows the administration of the protease to a patient positive for an antibody against the protease; or alternatively, allows the absorption of the antibody by a polypeptide or the like containing the neutralizing region provided by the present invention.

25 Disclosure of the Invention

[0016] As a result of conducting diligent studies for attaining the isolation and identification of vWF-cleaving protease under the above-described circumstances, the present inventors successfully purified and isolated heretofore unreported vWF-cleaving protease of interest and identified an amino acid sequence of a mature protein thereof and a gene encoding the amino acid sequence in the previous application (JP Patent Publication (Kokai) No. 2003-284570).

30 **[0017]** Based on the findings obtained using genetic recombination techniques described in the previous application (JP Patent Publication (Kokai) No. 2003-284570), the present inventors identified a region likely to be essential for activity expression (JP Patent Application No. 2002-279924). From the results of using a mutant molecule prepared on the basis of these findings to analyze a major neutralizing region recognized by an autoantibody against anti-ADAMTS-13 in an acquired TTP patient in the present invention, it has been revealed that the region recognized by the autoantibody is in agreement with the above-described region likely to be essential for activity expression and is located in a region from a Cys-rich region (at approximately position 499) to a spacer region (at approximately position 687). Accordingly, a principal requirement of a major neutralizing epitope region provided by the present invention for an anti-ADAMTS-13 antibody is the region from the Cys-rich region (at approximately position 499) to the spacer region (at approximately position 687) in a polypeptide composing ADAMTS-13 or a peptide fragment having an equivalent amino acid sequence. That is, the present invention relates to a polypeptide comprising a neutralizing epitope region in von Willebrand factor-specific cleaving protease (hereinafter, also referred to as vWFCP or ADAMTS-13), which is recognized by an antibody against the protease, or a peptide fragment derived from the polypeptide. The neutralizing epitope region in the polypeptide or the peptide fragment derived from the polypeptide that is claimed in claim 1 is located in a region from position 449 to position 687 in an amino acid sequence shown in SEQ ID No. 1. The present invention is further intended to a polypeptide consisting of an amino acid sequence from position 449 to position 687 in an amino acid sequence shown in SEQ ID No. The polypeptide is recognized by an antibody against von Willebrand factor-specific cleaving protease.

35 **[0018]** Using, as an antigen, a polypeptide or the like of the neutralizing epitope region, which is prepared on the basis of the amino acid sequence of ADAMTS-13 obtained by this finding, for example, monoclonal and polyclonal antibodies can be created by a typical immunization method (Current Protocols in Molecular Biology, edited by F.M. Ausbel et al., (1987); Antibody Engineering: A PRACTICAL APPROACH, edited by J. McCafferty et al., (1996); Antibodies: A Laboratory Manual, edited by Harlow David Lane (1988); or ANTIBODY ENGINEERING second edition, edited by Carl A.K. BORREBAECK (1995)). Alternatively, an antibody binding to the protein (ADAMTS-13) can be created by a technique of creating an antibody by use of a phage display technique (Phage Display of Peptides and Proteins: A Laboratory Manual, edited by Brian K. Kay et al., (1996); Antibody Engineering: A PRACTICAL APPROACH, edited by J. McCafferty et al., (1996); or ANTIBODY ENGINEERING second edition, edited by Carl A.K. BORREBAECK (1995)). Based on these techniques, a neutralizing antibody for the activity of the protease of the present invention or an antibody simply binding to the protease can also be isolated from a sample from a TTP patient positive for an autoantibody against the

protease of the present invention. In addition, the use of these antibodies allows the application of the present invention to diagnosis and treatment for a disease associated with variations in the amount of the protease of the present invention, for example, TTP.

5 **[0019]** In one embodiment, the present invention relates to a reagent for antibody measurement comprising the inventive polypeptide in a method of diagnosing a patient with a TTP-like disease or a patient at risk of developing vWF-dependent thrombosis, and the method comprises steps below.

10 **[0020]** Diagnostic assay for a disease associated with variations in the amount of the protease of the present invention is performed using a biological sample from the patient. Such a sample can be used directly in the assay or, in some cases, can need to be subjected prior to the assay to treatment such as the removal of possible interfering substances in the sample. Examples of suitable biological samples include blood, urine, sweat, tissue, or serum. The method involves detecting an autoantibody against a WF-cleaving protease polypeptide as defined in the claims in the biological sample. The steps of the method are as follows:

15 (a) bringing a biological sample obtained from the patient into contact with a solid support in which the polypeptide of claim 1 is immobilized;

(b) bringing the solid support into contact with an anti-human immunoglobulin antibody labeled with a developer; and

(c) detecting the label of the specifically bound developer in the step (b) in order to obtain a value corresponding to the concentration of an anti-ADAMTS-13 antibody in the sample.

20 **[0021]** The above-described diagnosis can be conducted by immunoassay known in the art. Solid supports that can be used include beads and plates made of a resin such as polystyrene. Developers that can be used include radioisotopes, enzymes such as peroxidase and alkaline phosphatase, and fluorescent substances.

25 **[0022]** In an alternative embodiment of the present invention, the polypeptide of the present invention is also useful as a neutralizing agent in a pharmaceutical composition for use in treating a patient positive for an anti-ADAMTS-13 antibody or as a removing agent for an autoantibody. In this case, the neutralization of the autoantibody refers to binding to the autoantibody, thereby inhibiting the binding of the autoantibody to vWF-cleaving protease. In this method, the polypeptide is optionally immobilized in a suitable support or the like using a method known in the art. Subsequently, a sample containing an anti-ADAMTS-13 antibody to be removed, for example, blood from the patient is brought into contact with the immobilized polypeptide to thereby remove the autoantibody from the sample from the patient. On this occasion, a carrier bound with a ligand specific to the anti-ADAMTS-13 antibody is brought into contact with blood or plasma from the patient and the anti-ADAMTS-13 antibody in the blood or the plasma is bound to the ligand to thereby remove the antibody from the blood or the plasma. Subsequently, the blood or the plasma from which the antibody have been removed may be reinjected to the patient. The above-described polypeptide can be used as the ligand specific to the anti-ADAMTS-13 antibody. The contact may be performed, for example, by allowing the blood or plasma from the patient to pass through the carrier bound with the ligand. The present invention further encompasses a method of producing blood or plasma free from an anti-ADAMTS 13 antibody by bringing a carrier bound with the above-described polypeptide or peptide fragment derived from the polypeptide into contact with blood or plasma from a patient positive for an anti-ADAMTS-13 antibody and binding an anti-ADAMTS-13 antibody in the blood or the plasma to the ligand to remove the antibody from the blood or the plasma.

35 **[0023]** A neutralizing agent for an autoantibody administered to a patient positive for an anti-ADAMTS-13 antibody is a pharmaceutical composition for treating a patient positive for an anti-ADAMTS-13 antibody comprising, as an active ingredient, the above-described polypeptide. When the polypeptide of the present invention recognized by an ADAMTS-13 antibody is used, for example, as a neutralizing agent for an autoantibody by administering the polypeptide to a patient positive for an anti-ADAMTS-13 antibody, the polypeptide can be diluted with a saline, a buffer solution, or the like, and made into a preparation to obtain a pharmaceutical composition. The pH of the preparation is preferably in the pH range from weakly-acidic pH to neutral pH, which is close to body fluid pH; a lower limit thereof is preferably from pH 5.0 to 6.4 and an upper limit thereof is preferably from pH 6.4 to 7.4. The preparation can also be provided in a form storable for a long period such as a freeze-dried form. In this case, when used, the preparation can be dissolved in water, a saline, a buffer solution, or the like, and then used at a desired concentration. The preparation of the present invention may contain pharmacologically acceptable additives (e.g., carriers, excipients, and diluents) and stabilizers that are usually used in drugs or other ingredients that are pharmaceutically required. The stabilizers are exemplified by monosaccharides such as glucose, disaccharides such as saccharose and maltose, sugar alcohols such as mannitol and sorbitol, neutral salts such as sodium chloride, amino acids such as glycine, nonionic surfactants such as polyethylene glycol, a polyoxyethylene-polyoxypropylene copolymer (Pluronic), and polyoxyethylene sorbitan fatty acid ester (Tween), and human albumin. It is preferred that any of these stabilizers on the order of 1 to 10 w/v% should be added to the preparation.

50 **[0024]** The pharmaceutical composition of the present invention can be administered in an effective amount by, for example, intravenous injection, intramuscular injection, or subcutaneous injection and is administered in a single dosage

or several dosages. The dosage varies depending on the symptom, age, body weight, and so on, of a patient and is preferably 0.001 mg to 100 mg per dosage.

Brief Description of the Drawings

5

[0025]

Figure 1 is a diagram showing a method of producing a C-terminus deletion mutant for determining an epitope for an antibody;

10 Figure 2 is a photograph in which the expression and abundance of the prepared C-terminus deletion mutant has been confirmed by Western blotting under non-reducing conditions using an anti-FLAG antibody;

Figure 3 is a photograph in which a region recognized by purified IgG derived from an acquired TTP patient 003 has been confirmed by Western blotting under non-reducing conditions;

15 Figure 4 is a photograph in which a region recognized by purified IgG derived from an acquired TTP patient 004 has been confirmed by Western blotting under non-reducing conditions;

Figure 5 is a photograph in which a region recognized by purified IgG derived from an acquired TTP patient 009 has been confirmed by Western blotting under non-reducing conditions; and

Figure 6 is a photograph in which a more precise region recognized by purified IgG derived from the acquired TTP patients has been confirmed.

20

Best Mode for Carrying Out the Invention

Examples

25 Preparation Example 1

(Preparation of C-terminus deletion mutant of ADAMTS-13)

30 **[0026]** Expression vectors for full-length and mutant (sequentially lacking domains from the C terminus). (Full1427, and T1135X, W1016X, W897X, W808X, W746X, W688X, T581X, Q449X, W387X, and P285X; each numerical value represents the number of amino acid residues from Met encoded by an initiation codon ATG to a stop codon, and X represents a stop codon) genes described in the previous patent application (JP Patent Application No. 2002-279924) were utilized to perform transfection using Hela cells in the procedures below. Each mutant location in a full-length sequence is shown in Figure 1.

35 **[0027]** At first, 24 hours before transfection, $1-3 \times 10^5$ cells per 35-mm dish were seeded. On the following day, 10 μ l of the Polyamine Transfection Reagent TransIT (manufactured by TAKARA) per 2 μ g of each of the expression vectors was added to 200 μ l of a serum-free medium such as Opti-MEM to prepare a complex with DNA according to the instructions attached to the reagent. The complex was then added dropwise to the above-described various cells prepared in advance and was incubated for 6 hours. Seventy-two hours after the incubation, the medium was collected. The
40 detection of each appropriately concentrated mutant was conducted Western blotting using an anti-FLAG-M2 antibody (manufactured by Kodak) and staining with an anti-mouse IgG-alkaline phosphatase enzyme-labeled antibody system (the result of confirming the expression of the mutants is shown in Figure 2).

45 Example 1

(Analysis of epitope for antibody in acquired TTP patient using Western blotting)

50 **[0028]** IgG fractions (antibody concentration: 2 to 5 mg/ml) were prepared from plasma samples from acquired TTP patients using a protein A column according to a standard method, and diluted 200-fold to perform Western blotting. An IgG-alkaline phosphatase-labeled antibody was used as a secondary antibody in a filter, and the filter was stained with a BCIP/NBT substrate to visualize bands (Figures 3 to 5). The region thereby determined which is recognized by the antibody was confirmed to be located on the C-terminus side from the Q449X, because a region up to the W688X shows reactivity and a region at the Q449X shows no reactivity with all of the antibody fractions from the three patients,.

55 Example 2

(Analysis of precise epitope for antibody in acquired TTP patient using Western blotting based on principle of competitive inhibition)

5 **[0029]** For narrowing down the more precise location of the epitope recognized by the neutralizing antibody of the present invention, supernatants from the W688X mutant and the full-length wild-type ADAMTS-13 were subjected to electrophoresis and transferred to a PVDF membrane. The PVDF membrane was utilized in a competitive inhibition system using primary antibody reaction solutions obtained by previously preincubating the above-described antibodies from the patients with a concentrated supernatant having the considerable overexpression of the Q449X mutant, the W688X mutant, or the full-length wild-type ADAMTS-13. As a result, bands positive for the full-length wild type ADAMTS-13 for all of the samples were confirmed to disappear by the W688X mutant (Figure 6).

10 **[0030]** This has suggested that all of the antibodies from the three patients recognize a region located on the N-terminus side from the W688X.

15 **[0031]** From the results shown in Examples 1 and 2, a major neutralizing region for the autoantibodies used from the three patients was confirmed to be a region located on the terminus side of the Q449X and on the N-terminus side from the W688X, that is, a region from a Cys-rich region to a spacer region which is between the Q449X and the X688X.

Industrial Applicability

20 **[0032]** The findings brought about by the present invention demonstrate that a polypeptide of this invention shows specific immunoreactivity with an anti-ADAMTS-13 antibody. Therefore, the use of the polypeptide allows the rapid detection of the amount of the anti-ADAMTS-13 antibody, diagnosis for diseases associated with variations in the amount of a protease of the present invention, or the neutralization of the binding or inhibitory activity of the anti-ADAMTS-13 antibody. Thus, the polypeptide provided by the present invention provides a wide variety of applications including the detection of the anti-ADAMTS-13 antibody and other applications.

25 **[0033]** The present invention exhibits such remarkable action or effect and can be said to be an invention of great significance which contributes to every field.

SEQUENCE LISTING

30 **[0034]**

<110>JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE

35 <120>Composition comprising peptide fragment(s) recognized by antibody against von Willebrand Factor cleaving protease

<130>PH-2095PCT

40 <140>

<141>

<150> PCT/JP2004/003602

<151> 2004-03-17

45 <150> JP 2003/71979

<151> 2003-03-17

<160>18

50 <210>1

<211>1427

<212>PRT

<213>Homo sapiens

55 <400>1

EP 1 609 804 B1

Met His Gln Arg His Pro Arg Ala Arg Cys Pro Pro Leu Cys Val
1 5 10 15

5

Ala Gly Ile Leu Ala Cys Gly Phe Leu Leu Gly Cys Trp Gly Pro

10

15

20

25

30

35

40

45

50

55

EP 1 609 804 B1

	20	25	30
5	Ser His Phe Gln Gln Ser Cys Leu Gln Ala Leu Glu Pro Gln Ala		
	35	40	45
10	Val Ser Ser Tyr Leu Ser Pro Gly Ala Pro Leu Lys Gly Arg Pro		
	50	55	60
15	Pro Ser Pro Gly Phe Gln Arg Gln Arg Gln Arg Gln Arg Arg Ala		
	65	70	75
	Ala Gly Gly Ile Leu His Leu Glu Leu Leu Val Ala Val Gly Pro		
	80	85	90
20	Asp Val Phe Gln Ala His Gln Glu Asp Thr Glu Arg Tyr Val Leu		
	95	100	105
25	Thr Asn Leu Asn Ile Gly Ala Glu Leu Leu Arg Asp Pro Ser Leu		
	110	115	120
	Gly Ala Gln Phe Arg Val His Leu Val Lys Met Val Ile Leu Thr		
30	125	130	135
	Glu Pro Glu Gly Ala Pro Asn Ile Thr Ala Asn Leu Thr Ser Ser		
	140	145	150
35	Leu Leu Ser Val Cys Gly Trp Ser Gln Thr Ile Asn Pro Glu Asp		
	155	160	165
40	Asp Thr Asp Pro Gly His Ala Asp Leu Val Leu Tyr Ile Thr Arg		
	170	175	180
	Phe Asp Leu Glu Leu Pro Asp Gly Asn Arg Gln Val Arg Gly Val		
45	185	190	195
	Thr Gln Leu Gly Gly Ala Cys Ser Pro Thr Trp Ser Cys Leu Ile		
	200	205	210
50	Thr Glu Asp Thr Gly Phe Asp Leu Gly Val Thr Ile Ala His Glu		
	215	220	225
55	Ile Gly His Ser Phe Gly Leu Glu His Asp Gly Ala Pro Gly Ser		

	230	235	240
5	Gly Cys Gly Pro Ser Gly His Val Met Ala Ser Asp Gly Ala Ala		
	245	250	255
10	Pro Arg Ala Gly Leu Ala Trp Ser Pro Cys Ser Arg Arg Gln Leu		
	260	265	270
	Leu Ser Leu Leu Ser Ala Gly Arg Ala Arg Cys Val Trp Asp Pro		
15	275	280	285
	Pro Arg Pro Gln Pro Gly Ser Ala Gly His Pro Pro Asp Ala Gln		
	290	295	300
20	Pro Gly Leu Tyr Tyr Ser Ala Asn Glu Gln Cys Arg Val Ala Phe		
	305	310	315
25	Gly Pro Lys Ala Val Ala Cys Thr Phe Ala Arg Glu His Leu Asp		
	320	325	330
	Met Cys Gln Ala Leu Ser Cys His Thr Asp Pro Leu Asp Gln Ser		
30	335	340	345
	Ser Cys Ser Arg Leu Leu Val Pro Leu Leu Asp Gly Thr Glu Cys		
	350	355	360
35	Gly Val Glu Lys Trp Cys Ser Lys Gly Arg Cys Arg Ser Leu Val		
	365	370	375
40	Glu Leu Thr Pro Ile Ala Ala Val His Gly Arg Trp Ser Ser Trp		
	380	385	390
	Gly Pro Arg Ser Pro Cys Ser Arg Ser Cys Gly Gly Gly Val Val		
45	395	400	405
	Thr Arg Arg Arg Gln Cys Asn Asn Pro Arg Pro Ala Phe Gly Gly		
	410	415	420
50	Arg Ala Cys Val Gly Ala Asp Leu Gln Ala Glu Met Cys Asn Thr		
	425	430	435
55	Gln Ala Cys Glu Lys Thr Gln Leu Glu Phe Met Ser Gln Gln Cys		

EP 1 609 804 B1

	440	445	450
5	Ala Arg Thr Asp Gly Gln Pro Leu Arg Ser Ser Pro Gly Gly Ala		
	455	460	465
10	Ser Phe Tyr His Trp Gly Ala Ala Val Pro His Ser Gln Gly Asp		
	470	475	480
	Ala Leu Cys Arg His Met Cys Arg Ala Ile Gly Glu Ser Phe Ile		
15	485	490	495
	Met Lys Arg Gly Asp Ser Phe Leu Asp Gly Thr Arg Cys Met Pro		
	500	505	510
20	Ser Gly Pro Arg Glu Asp Gly Thr Leu Ser Leu Cys Val Ser Gly		
	515	520	525
25	Ser Cys Arg Thr Phe Gly Cys Asp Gly Arg Met Asp Ser Gln Gln		
	530	535	540
	Val Trp Asp Arg Cys Gln Val Cys Gly Gly Asp Asn Ser Thr Cys		
30	545	550	555
	Ser Pro Arg Lys Gly Ser Phe Thr Ala Gly Arg Ala Arg Glu Tyr		
	560	565	570
35	Val Thr Phe Leu Thr Val Thr Pro Asn Leu Thr Ser Val Tyr Ile		
	575	580	585
40	Ala Asn His Arg Pro Leu Phe Thr His Leu Ala Val Arg Ile Gly		
	590	595	600
	Gly Arg Tyr Val Val Ala Gly Lys Met Ser Ile Ser Pro Asn Thr		
45	605	610	615
	Thr Tyr Pro Ser Leu Leu Glu Asp Gly Arg Val Glu Tyr Arg Val		
	620	625	630
50	Ala Leu Thr Glu Asp Arg Leu Pro Arg Leu Glu Glu Ile Arg Ile		
	635	640	645
55	Trp Gly Pro Leu Gln Glu Asp Ala Asp Ile Gln Val Tyr Arg Arg		

	650	655	660
5	Tyr Gly Glu Glu Tyr Gly Asn Leu Thr Arg Pro Asp Ile Thr Phe		
	665	670	675
10	Thr Tyr Phe Gln Pro Lys Pro Arg Gln Ala Trp Val Trp Ala Ala		
	680	685	690
	Val Arg Gly Pro Cys Ser Val Ser Cys Gly Ala Gly Leu Arg Trp		
15	695	700	705
	Val Asn Tyr Ser Cys Leu Asp Gln Ala Arg Lys Glu Leu Val Glu		
	710	715	720
20	Thr Val Gln Cys Gln Gly Ser Gln Gln Pro Pro Ala Trp Pro Glu		
	725	730	735
25	Ala Cys Val Leu Glu Pro Cys Pro Pro Tyr Trp Ala Val Gly Asp		
	740	745	750
	Phe Gly Pro Cys Ser Ala Ser Cys Gly Gly Gly Leu Arg Glu Arg		
30	755	760	765
	Pro Val Arg Cys Val Glu Ala Gln Gly Ser Leu Leu Lys Thr Leu		
	770	775	780
35	Pro Pro Ala Arg Cys Arg Ala Gly Ala Gln Gln Pro Ala Val Ala		
	785	790	795
40	Leu Glu Thr Cys Asn Pro Gln Pro Cys Pro Ala Arg Trp Glu Val		
	800	805	810
	Ser Glu Pro Ser Ser Cys Thr Ser Ala Gly Gly Ala Gly Leu Ala		
45	815	820	825
	Leu Glu Asn Glu Thr Cys Val Pro Gly Ala Asp Gly Leu Glu Ala		
	830	835	840
50	Pro Val Thr Glu Gly Pro Gly Ser Val Asp Glu Lys Leu Pro Ala		
	845	850	855
55	Pro Glu Pro Cys Val Gly Met Ser Cys Pro Pro Gly Trp Gly His		

EP 1 609 804 B1

	860	865	870
5	Leu Asp Ala Thr Ser Ala Gly Glu Lys Ala Pro Ser Pro Trp Gly		
	875	880	885
10	Ser Ile Arg Thr Gly Ala Gln Ala Ala His Val Trp Thr Pro Ala		
	890	895	900
15	Ala Gly Ser Cys Ser Val Ser Cys Gly Arg Gly Leu Met Glu Leu		
	905	910	915
20	Arg Phe Leu Cys Met Asp Ser Ala Leu Arg Val Pro Val Gln Glu		
	920	925	930
25	Glu Leu Cys Gly Leu Ala Ser Lys Pro Gly Ser Arg Arg Glu Val		
	935	940	945
30	Cys Gln Ala Val Pro Cys Pro Ala Arg Trp Gln Tyr Lys Leu Ala		
	950	955	960
35	Ala Cys Ser Val Ser Cys Gly Arg Gly Val Val Arg Arg Ile Leu		
	965	970	975
40	Tyr Cys Ala Arg Ala His Gly Glu Asp Asp Gly Glu Glu Ile Leu		
	980	985	990
45	Leu Asp Thr Gln Cys Gln Gly Leu Pro Arg Pro Glu Pro Gln Glu		
	995	1000	1005
50	Ala Cys Ser Leu Glu Pro Cys Pro Pro Arg Trp Lys Val Met Ser		
	1010	1015	1020
55	Leu Gly Pro Cys Ser Ala Ser Cys Gly Leu Gly Thr Ala Arg Arg		
	1025	1030	1035
60	Ser Val Ala Cys Val Gln Leu Asp Gln Gly Gln Asp Val Glu Val		
	1040	1045	1050
65	Asp Glu Ala Ala Cys Ala Ala Leu Val Arg Pro Glu Ala Ser Val		
	1055	1060	1065
70	Pro Cys Leu Ile Ala Asp Cys Thr Tyr Arg Trp His Val Gly Thr		

	1070	1075	1080
5	Trp Met Glu Cys Ser Val Ser Cys Gly Asp Gly Ile Gln Arg Arg		
	1085	1090	1095
10	Arg Asp Thr Cys Leu Gly Pro Gln Ala Gln Ala Pro Val Pro Ala		
	1100	1105	1110
15	Asp Phe Cys Gln His Leu Pro Lys Pro Val Thr Val Arg Gly Cys		
	1115	1120	1125
	Trp Ala Gly Pro Cys Val Gly Gln Gly Thr Pro Ser Leu Val Pro		
	1130	1135	1140
20	His Glu Glu Ala Ala Ala Pro Gly Arg Thr Thr Ala Thr Pro Ala		
	1145	1150	1155
25	Gly Ala Ser Leu Glu Trp Ser Gln Ala Arg Gly Leu Leu Phe Ser		
	1160	1165	1170
	Pro Ala Pro Gln Pro Arg Arg Leu Leu Pro Gly Pro Gln Glu Asn		
30	1175	1180	1185
	Ser Val Gln Ser Ser Ala Cys Gly Arg Gln His Leu Glu Pro Thr		
	1190	1195	1200
35	Gly Thr Ile Asp Met Arg Gly Pro Gly Gln Ala Asp Cys Ala Val		
	1205	1210	1215
40	Ala Ile Gly Arg Pro Leu Gly Glu Val Val Thr Leu Arg Val Leu		
	1220	1225	1230
	Glu Ser Ser Leu Asn Cys Ser Ala Gly Asp Met Leu Leu Leu Trp		
45	1235	1240	1245
	Gly Arg Leu Thr Trp Arg Lys Met Cys Arg Lys Leu Leu Asp Met		
	1250	1255	1260
50	Thr Phe Ser Ser Lys Thr Asn Thr Leu Val Val Arg Gln Arg Cys		
	1265	1270	1275
55	Gly Arg Pro Gly Gly Gly Val Leu Leu Arg Tyr Gly Ser Gln Leu		

	1280	1285	1290
5	Ala Pro Glu Thr Phe Tyr Arg Glu Cys Asp Met Gln Leu Phe Gly		
	1295	1300	1305
10	Pro Trp Gly Glu Ile Val Ser Pro Ser Leu Ser Pro Ala Thr Ser		
	1310	1315	1320
	Asn Ala Gly Gly Cys Arg Leu Phe Ile Asn Val Ala Pro His Ala		
15	1325	1330	1335
	Arg Ile Ala Ile His Ala Leu Ala Thr Asn Met Gly Ala Gly Thr		
	1340	1345	1350
20	Glu Gly Ala Asn Ala Ser Tyr Ile Leu Ile Arg Asp Thr His Ser		
	1355	1360	1365
25	Leu Arg Thr Thr Ala Phe His Gly Gln Gln Val Leu Tyr Trp Glu		
	1370	1375	1380
	Ser Glu Ser Ser Gln Ala Glu Met Glu Phe Ser Glu Gly Phe Leu		
30	1385	1390	1395
	Lys Ala Gln Ala Ser Leu Arg Gly Gln Tyr Trp Thr Leu Gln Ser		
	1400	1405	1410
35	Trp Val Pro Glu Met Gln Asp Pro Gln Ser Trp Lys Gly Lys Glu		
	1415	1420	1425
40	Gly Thr		
	1427		

45 <210>2
 <211>30
 <212>DNA
 <213>Homo sapiens

50 <400>2
 ctggagcacg acggcgcgcc cggcagcggc 30

55 <210>3
 <211>30
 <212>DNA
 <213>Homo sapiens

<400>3

EP 1 609 804 B1

atgtgcaaca ctcaggcctg cgagaagacc 30

<210>4
<211>30
<212>DNA
<213>Homo sapiens

<400>4
ccaacctgac cagtgctac attgccaacc 30

<210>5
<211>21
<212>DNA
<213>Homo sapiens

<400>5
ctggagccct gccacctag g 21

<210>6
<211>62
<212>DNA
<213>Homo sapiens

<400>6

tccgtcgact cttatcactt atcgtcatcg tccttgtagt cgtcccacac gcagcgcgcc 60

cg 62

<210>7
<211>62
<212>DNA
<213>Homo sapiens

<400>7

tccgtcgact cttatcactt atcgtcatcg tccttgtagt cgcgccatg cactgctgct 60

at 62

<210>8
<211>62
<212>DNA
<213>Homo sapiens

<400>8

EP 1 609 804 B1

gccgtcgact cttatcactt atcgtcatcg tcctttagt cttgcgacat gaactccagc 60
tg 62
 5
 <210>9
 <211>62
 <212>DNA
 10 <213>Homo sapiens
 <400>9
 15 **gccgtcgact cttatcactt atcgtcatcg tcctttagt ccaggttggg ggtaactgtc 60**
ag 62
 20
 <210>10
 <211>62
 <212>DNA
 <213>Homo sapiens
 25 <400>10
 30 **tccgtcgact cttatcactt atcgtcatcg tcctttagt ccaccaggc ctgccgtggc 60**
tt 62
 35
 <210>11
 <211>62
 <212>DNA
 <213>Homo sapiens
 40 <400>11
 45 **tccgtcgact cttatcactt atcgtcatcg tcctttagt cgtagggagg gcagggttcg 60**
ag 62
 50
 <210>12
 <211>62
 <212>DNA
 <213>Homo sapiens
 55 <400>12
 55 **tccgtcgact cttatcactt atcgtcatcg tcctttagt ccctggcagg gcagggctgg 60**
gg 62

EP 1 609 804 B1

<210>13
 <211>62
 <212>DNA
 <213>homo sapiens
 5
 <400>13

gccgtcgact cttatcactt atcgatcatcg tcctttagt ccacgtgtgc agcttgagcc 60
 10

cc 62
 15

 <210>14
 <211>62
 <212>DNA
 <213>Homo sapiens
 20
 <400>14

gccgtcgact cttatcactt atcgatcatcg tcctttagt ccctaggtgg gcagggctcc 60
 25
ag 62
 30
 <210>15
 <211>62
 <212>DNA
 <213>Homo sapiens
 35
 <400>15

gccgtcgact cttatcactt atcgatcatcg tcctttagt caccctgtcc cacacagggc 60
 40
cc 62
 45
 <210>16
 <211>60
 <212>DNA
 <213>Homo sapiens
 <400>16
 tccaagcttg tcgactcta tcacttatcg tcatcgtcct ttagtcggt tcctcctt 60
 50
 <210>17
 <211>27
 <212>DNA
 <213>Artificial Sequence
 55
 <220>
 <223>Description of Artificial Sequence:Synthetic DNA
 <400>17

gactacaagg acgatgacga taagtga 27

<210>18

<211>8

<212>RPT

<213>Artificial Sequence

<220>

<223>Description of Artificial Sequence:Synthetic peptide

<400>18

Asp Tyr Lys Asp Asp Asp Asp Lys

1

5

Claims

1. A polypeptide consisting of an amino acid sequence from position 449 to position 687 in an amino acid sequence shown in SEQ ID No. 1.
2. A reagent for antibody measurement comprising a polypeptide according to claim 1.
3. The reagent for antibody measurement according to claim 2, wherein an autoantibody in a TTP (thrombotic thrombocytopenic purpura) patient is an object to be detected, *in vitro*.
4. A pharmaceutical composition for use in treating a TTP patient positive for an anti-ADAMTS-13 antibody comprising, as an active ingredient, a polypeptide according to claim 1.
5. The pharmaceutical composition for use in treating a TTP patient positive for an anti-ADAMTS-13 antibody according to claim 4, wherein the pharmaceutical composition is administered to the patient to thereby neutralise the antibody.
6. A composition comprising a ligand specific to an anti-ADAMTS-13 antibody for use in treating a TTP patient positive for an anti-ADAMTS-13 antibody, comprising, as an active ingredient, a polypeptide according to claim 1, which is bound with a carrier and brought into contact with plasma from the patient to be used for removing the anti-ADAMTS-13 antibody from the plasma from the patient.
7. A method of producing blood or plasma free from an anti-ADAMTS-13 antibody by bringing a carrier bound with a polypeptide according to claim 1 into contact with blood or plasma from a patient positive for an anti-ADAMTS-13 antibody and binding an anti-ADAMTS-13 antibody in the blood or the plasma to the ligand to remove the anti-ADAMTS-13 antibody from the blood or the plasma.

Patentansprüche

1. Polypeptid, bestehend aus einer Aminosäuresequenz von Position 449 bis Position 687 in der in SEQ ID NO: 1 gezeigten Aminosäuresequenz.
2. Reagenz zur Antikörpermessung, umfassend ein Polypeptid gemäß Anspruch 1.
3. Reagenz zur Antikörpermessung gemäß Anspruch 2, wobei ein Autoantikörper in einem TTP (thrombotisches thrombocytopenisches Purpura)-Patienten ein *in vitro* nachzuweisender Gegenstand ist.
4. Pharmazeutische Zusammensetzung zur Verwendung bei der Behandlung eines TTP-Patienten, der positiv für einen Anti-ADAMTS-13-Antikörper ist, umfassend ein Polypeptid gemäß Anspruch 1 als aktiven Bestandteil.

EP 1 609 804 B1

5. Pharmazeutische Zusammensetzung zur Verwendung bei der Behandlung eines TTP-Patienten, der positiv für einen Anti-ADAMTS-13-Antikörper ist, gemäß Anspruch 4, wobei die pharmazeutische Zusammensetzung dem Patienten verabreicht wird, um **dadurch** den Antikörper zu neutralisieren.
- 5 6. Zusammensetzung, umfassend einen Liganden, der spezifisch für einen Anti-ADAMTS-13-Antikörper ist, zur Verwendung bei der Behandlung eines TTP-Patienten, der positiv für einen Anti-ADAMTS-13-Antikörper ist, umfassend ein Polypeptid gemäß Anspruch 1 als aktiven Bestandteil, welches an einen Träger gebunden ist und mit Plasma des Patienten in Kontakt gebracht wird und zum Entfernen des Anti-ADAMTS-13-Antikörpers aus dem Plasma des Patienten verwendet werden soll.
- 10 7. Verfahren zum Herstellen von Blut oder Plasma, das frei von einem Anti-ADAMTS-13-Antikörper ist, durch In-Kontakt-Bringen eines Trägers, an den ein Polypeptid gemäß Anspruch 1 gebunden ist, mit Blut oder Plasma von einem Patienten, der positiv für einen Anti-ADAMTS-13-Antikörper ist, und Binden eines Anti-ADAMTS-13-Antikörpers im Blut oder Plasma an den Liganden, um den Anti-ADAMTS-13-Antikörper aus dem Blut oder dem Plasma zu entfernen.
- 15

Revendications

- 20 1. Polypeptide constitué d'une séquence d'acides aminés de la position 449 à la position 687 dans une séquence d'acides aminés présentée dans SEQ ID No. 1.
2. Réactif pour une mesure d'anticorps comprenant un polypeptide selon la revendication 1.
- 25 3. Réactif pour une mesure d'anticorps selon la revendication 2, dans lequel un auto-anticorps chez un patient atteint de PTT (purpura thrombotique thrombocytopénique) est un objet à détecter, *in vitro*.
4. Composition pharmaceutique pour une utilisation dans le traitement d'un patient atteint de PTT positif pour un anticorps anti-ADAMTS-13 comprenant, en tant que principe actif, un polypeptide selon la revendication 1.
- 30 5. Composition pharmaceutique pour une utilisation dans le traitement d'un patient atteint de PTT positif pour un anticorps anti-ADAMTS-13 selon la revendication 4, dans laquelle la composition pharmaceutique est administrée au patient pour neutraliser par ce moyen l'anticorps.
- 35 6. Composition comprenant un ligand spécifique d'un anticorps anti-ADAMTS-13 destinée à une utilisation dans le traitement d'un patient atteint de PTT positif pour un anticorps anti-ADAMTS-13, comprenant, en tant que principe actif, un polypeptide selon la revendication 1, qui est lié à un support et mis en contact avec le plasma provenant du patient à utiliser pour enlever l'anticorps anti-ADAMTS-13 du plasma du patient.
- 40 7. Procédé de production de sang ou de plasma sans anticorps anti-ADAMTS-13 par la mise au contact d'un support lié à un polypeptide selon la revendication 1 avec du sang ou du plasma d'un patient positif pour un anticorps anti-ADAMTS-13 et la liaison d'un anticorps anti-ADAMTS-13 dans le sang ou le plasma au ligand pour enlever l'anticorps anti-ADAMTS-13 du sang ou du plasma.
- 45
- 50
- 55

Fig. 1




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5






Fig. 6



1. Patient 003 IgG with Q449 sup
2. Patient 003 IgG with W688 sup
3. Patient 003 IgG with Full sup
4. Patient 004 IgG with Q449 sup
5. Patient 004 IgG with W668 sup
6. Patient 004 IgG with Full sup
7. Patient 009 IgG with Q449 sup
8. Patient 009 IgG with W688 sup
9. Patient 009 IgG with Full sup

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- JP 2003284570 A [0006] [0016] [0017]
- JP 2002279924 A [0015] [0017] [0026]
- JP 2004003602 W [0034]
- JP 2003071979 A [0034]

Non-patent literature cited in the description

- Current Protocols in Molecular Biology. 1987 [0018]
- Antibody Engineering: A PRACTICAL APPROACH. 1996 [0018]
- Antibodies: A Laboratory Manual. 1988 [0018]
- ANTIBODY ENGINEERING. 1995 [0018]
- Phage Display of Peptides and Proteins: A Laboratory Manual. 1996 [0018]

专利名称(译)	构建体包含针对血管性血友病因子特异性切割酶的抗体的识别结构域		
公开(公告)号	EP1609804A4	公开(公告)日	2006-07-05
申请号	EP2004721377	申请日	2004-03-17
申请(专利权)人(译)	法律基础，化学及血清疗法研究所		
当前申请(专利权)人(译)	法律基础，化学及血清疗法研究所		
[标]发明人	SOEJIMA KENJI THE CHEMO SERO THERAPEUTIC R I NAKAGAKI TOMOHIRO CHEMO SERO THER R I MATSUMOTO MASANORI FUJIMURA YOSHIHIRO		
发明人	SOEJIMA, KENJI, THE CHEMO-SERO-THERAPEUTIC R. I. NAKAGAKI, TOMOHIRO, CHEMO-SERO-THER. R. I. MATSUMOTO, MASANORI FUJIMURA, YOSHIHIRO		
IPC分类号	A61P7/04 C07K16/40 C12N9/64 A61K39/00 G01N33/53 G01N33/564		
CPC分类号	C12N9/6489 A61K2039/505 C07K16/40		
优先权	2003071979 2003-03-17 JP		
其他公开文献	EP1609804A1 EP1609804B1		
外部链接	Espacenet		

摘要(译)

本发明提供抗体识别的表位(下文中,也称为抗ADAMTS-13抗体)针对血管性血友病因子特异性的裂解蛋白酶(下文中,也称为ADAMTS-13)(下文中,也称为抗体)。作为vWF)和包含表位区域的多肽。本发明还提供了位于组成ADAMTS-13的氨基酸序列中第449位至第687位的区域的多肽,其被抗ADAMTS-13抗体识别,或者衍生自该多肽的肽片段。

